There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for 10x Genomics Inc. (TXG) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.75, or 2.00%, to $38.32. The 10x Genomics Inc. has recorded 7,303 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed 10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
This NASDAQ-listed company operates within the Health Information Services industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $37.57 and fluctuated between $38.00 as its day high and $35.05 as its day low. The current market capitalization of 10x Genomics Inc. is $4.32B. A total of 1.06 million shares were traded on the day, compared to an average of 1.29M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, TXG has seen 0 BUY and 9 SELL insider trades, representing the acquisition of 0 and the disposition of 8,403 shares. Over the last 12 months, there were 20 BUYs and 34 SELLs from insiders. Insiders purchased 345,102 shares during that period but sold 67,348.
In the most recent transaction, Saxonov Serge sold 2,676 shares of TXG for 34.07 per share on Nov 22. After the transaction, the Chief Executive Officer now owns 974,926 company shares. In a previous transaction on Nov 22, McAnear Justin J. sold 1,626 shares at 34.07 per share. TXG shares that Chief Financial Officer owns now total 76,764.
Among the insiders who sold shares, Hindson Benjamin J. disposed of 2,361 shares on Nov 22 at a per-share price of $34.07. This resulted in the insider holding 217,713 shares of TXG after the transaction. In another insider transaction, McAnear Justin J. sold 987 shares at $35.19 per share on Aug 23. Company shares held by the Chief Financial Officer now total 58,092.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for TXG in the last 3 months, the mean price target is $49.67 with high estimates of $65.00 and low estimates of $25.00. In terms of 52-week highs and lows, TXG has a high of $144.09 and a low of $23.81.
As of this writing, TXG has an earnings estimate of -$0.46 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$0.61. The company reported an EPS of -$0.38 in the last quarter, which was -22.60% lower than expectations of -$0.31.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 11 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TXG is Hold with a score of 3.89. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.